Dilute Epinephrine vs Tourniquet for Visualization in Ankle Arthroscopy: A RCT

Study Objective and Design

This study aims to evaluate the effect of dilute epinephrine irrigation versus tourniquet use on visual field clarity (VFC) during ankle arthroscopic surgery, while also assessing the incidence of hypotension/bradycardia events and potential cardiovascular adverse effects.

This is a multicenter, prospective, randomized controlled trial comparing the intraoperative arthroscopic field clarity between patients receiving epinephrine-containing irrigation and those undergoing surgery with a tourniquet.

Participants are randomized into two groups:

Epinephrine Group: Irrigation fluid consists of normal saline mixed with 1 mL of 1:1000 epinephrine per 3-liter bag. A tourniquet is placed but not inflated; it may be inflated as a rescue measure if necessary.

Tourniquet Group: Standard tourniquet application as routinely practiced.

3.2.4 Primary Efficacy Outcome

Visual field clarity (VFC) under ankle arthroscopy, assessed using a Likert-style 4-point numeric rating scale (NRS).

3.2.5 Secondary Efficacy Outcomes

Pain intensity scores at 2 and 24 hours postoperatively, measured using the Visual Analog Scale (VAS).

Inclusion criteria

• Able to understand the procedures and methods of the clinical trial
• voluntarily provide written informed consent
• Aged from 15 to 65 years old , regardless of sex
• Diagnosed with a condition requiring ankle surgery
• Be scheduled to undergo unilateral ankle arthroscopy

Exclusion criteria

• Patients who decline to participate in the study
• Known history of heart disease (e.g., coronary artery disease, cardiac conduction abnormalities), diabetes, or asthma
• Poorly controlled hypertension
• Age under 15 years or above 65 years old
• Intellectual disability
• Pregnant or breastfeeding women
• Known allergy to sulfites

Contraindications to ISBPB (including planned injection site infection, pre-existing neurological deficits, allergy to local anesthetics, severe chronic obstructive pulmonary disease, or contralateral phrenic nerve dysfunction)